Samuel Blackman
Founder chez DAY ONE BIOPHARMACEUTICALS, INC.
Fortune : 36 M $ au 31/03/2024
Profil
Samuel C.
Blackman is the founder of Day One Biopharmaceuticals, Inc. where he currently holds the title of Head-Research & Development since 2023.
He is also the founder of DOT Therapeutics-2, Inc. Dr. Blackman's former job positions include Senior Medical Director at Juno Therapeutics, Inc. from 2014 to 2016, Head-Clinical Development at Silverback Therapeutics, Inc. from 2016 to 2018, and Head-Clinical Development at Mavupharma, Inc. from 2018 to 2019.
Dr. Blackman's education includes undergraduate and doctorate degrees from the University of Illinois.
Dr. Blackman is also the founder of DOT Therapeutics-2, Inc...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/04/2024 | 2 174 662 ( 2,49% ) | 36 M $ | 31/03/2024 |
Postes actifs de Samuel Blackman
| Sociétés | Poste | Début |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Founder | 01/11/2018 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Founder | - |
Anciens postes connus de Samuel Blackman
| Sociétés | Poste | Fin |
|---|---|---|
Mavupharma, Inc.
 Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Corporate Officer/Principal | 01/07/2019 |
| ARS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2018 |
| JUNO THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 01/08/2016 |
Formation de Samuel Blackman
| University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
